Germline pathogenic variants in chromatin-modifying enzymes are a common cause of pediatric developmental disorders. These enzymes catalyze reactions that regulate epigenetic inheritance via histone post-translational modifications and DNA methylation. Cytosine methylation of DNA (5mC) is the quintessential epigenetic mark, yet no human Mendelian disorder of DNA demethylation has been delineated. Here, we describe in detail the first Mendelian disorder caused by disruption of DNA demethylation. TET3 is a methylcytosine dioxygenase that initiates DNA demethylation during early zygote formation, embryogenesis, and neuronal differentiation and is intolerant to haploinsufficiency in mice and humans. Here we identify and characterize 11 cases of human TET3 deficiency in 8 families with the common phenotypic features of intellectual disability/global developmental delay, hypotonia, autistic traits, movement disorders, growth abnormalities, and facial dysmorphism. Mono-allelic frameshift and nonsense variants in TET3 occur throughout the coding region. Mono-allelic and bi-allelic missense variants localize to conserved residues with all but one occurring within the catalytic domain and most displaying hypomorphic function in a catalytic activity assay. TET3 deficiency shows substantial phenotypic overlap with other Mendelian disorders of the epigenetic machinery, including intellectual disability and growth abnormalities, underscoring shared disease mechanisms.
Introduction
Post-translational modifications of histone tails and DNA methylation play essential roles in development by regulating chromatin structure and gene expression. Inherited conditions that disrupt these processes -chromatin-modifying enzyme disorders or Mendelian disorders of the epigenetic machinery -account for a substantial percentage of neurodevelopmental and growth abnormalities in children 1; 2 . Most known disorders in this class are caused by pathogenic variants in histone-modifying enzymes and chromatin remodelers. Far fewer have been linked to deficiencies in the DNA methylation machinery [3] [4] [5] . The latter include disorders caused by defects in DNA methylation "writers," or DNA methyltransferases (DNMTs), such as immunodeficiencycentromeric instability-facial anomalies syndrome-1 (ICF syndrome) due to bi-allelic variants in DNMT3B (MIM: 242860), and Tatton-Brown-Rahman syndrome due to mono-allelic variants in DNMT3A (MIM: 615879), or by defects in reader proteins that bind to DNA methylation, such as Rett syndrome, which is caused by variants in MECP2 (MIM: 312750) [3] [4] [5] . No Mendelian disorder has been linked to the multi-step and tightly regulated process that removes DNA methylation.
The roles of DNMTs and proteins like MECP2 in "writing" and "reading" methyl marks on DNA have been known for decades, whereas the existence of enzymes that can actively reverse or "erase" DNA methylation was discovered more recently 6; 7 . The ten-eleven translocase (TET) family of enzymes consists of three methylcytosine dioxygenases (TET1, TET2, and TET3) that initiate DNA demethylation through a series of sequential oxidation reactions converting 5-methyl cytosine (5mC) first to 5-hydroxymethylcytosine (5hmC) and then to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC), which are removed either passively by replication-dependent dilution or actively by thymidine DNA glycosylase 8 . The process ultimately results in loss of the methylated base and replacement with an unmethylated cytosine 6; 7; 9; 10 , effectively leading to DNA demethylation.
In addition to being an intermediate in the active removal of 5mC, 5hmC is suggested to have an independent role in gene regulation, though the exact nature remains unclear. Notably, 5hmC levels differ globally based on cell lineage and are particularly enriched in mammalian brains 8; 11 . 5fC and 5caC are less well understood and may have unique functions as well 8 . Tet3 is highly expressed in oocytes, zygotes, and neurons, and ablation of Tet3 in mice leads to embryonic lethality 8 . TET3 plays an important role in rapidly demethylating the paternal genome after fertilization, producing genome-wide increases in the oxidized 5mC intermediates 5hmC, 5fC, and 5caC [12] [13] [14] [15] [16] . Importantly, Tet3 haploinsufficiency causes neonatal sublethality or sub-Mendelian ratios in mice 17 . Furthermore, inhibition or depletion of Tet3 in mouse differentiated neurons can impact synaptic function [18] [19] [20] . In humans, TET3 is highly intolerant to loss-of-function alleles in control databases 21 , and homozygous missense variants in TET3 were recently implicated as a possible cause for autosomal recessive intellectual disability in a single consanguineous family (further described here as family 3) 22 . Together, these findings illustrate the important role of TET3 in early embryonic development and neuronal function.
Here, we provide the first detailed description of a cohort of individuals with a Mendelian disorder due to disruption of the DNA demethylation machinery, namely the TET3 enzyme.
Whereas inheritance patterns vary and include both autosomal dominant and autosomal
recessive forms, all affected individuals have in common a deficiency in TET3 function. This is either due to one or more missense variants within the highly conserved catalytic domain, most of which have been functionally validated to possess decreased TET3 activity, or to a single frameshift or nonsense variant. The phenotype is remarkably similar between affected individuals and is consistent with the broader group of Mendelian disorders of the epigenetic machinery, which often show global developmental delay/intellectual disability and other neurological manifestations, growth abnormalities, and characteristic craniofacial features 1 23 24 .
Results
Individual 1 presented with developmental delay, generalized overgrowth including macrocephaly, and some facial features reminiscent of Sotos syndrome ( Table 1) Figure 1 ).
To delineate the phenotypic spectrum associated with variants in TET3 we collected detailed clinical information on all affected individuals, who ranged in age from 11 months to 43 years at the time of assessment ( Table 1) . We observed striking phenotypic overlap among affected individuals ( Table 1) . All had global developmental delay and/or intellectual disability, and the vast majority had hypotonia and/or joint hypermobility (9/11). Other commonly observed findings were autistic features including difficulty with social interactions (6/11), growth abnormalities (8/11), movement disorders (5/11), and overlapping common facial characteristics ( Figure 1) . The developmental delay/intellectual disability ranged from mild to severe and included gross motor delay with or without speech delay in almost all cases ( Table 1) . Seizures and/or EEG abnormalities occurred in 4/11 individuals; other movement disorders were also noted and included tics, dystonia, extensor posturing, and myoclonic jerks ( Table 1) . Brain MRI demonstrated non-specific abnormalities in two individuals, including periventricular white matter changes and increased extra-axial spaces including ventriculomegaly ( Table 1) . Postnatal growth abnormalities were identified in 7/11 affected individuals, most often involving head size, with three individuals (1, 4, and 5) having true macrocephaly (OFC ≥ +2SD above the mean), one (6) having borderline/relative macrocephaly, and two (3-I and 3-III) having microcephaly ( Table 1) .
In individual 1, macrocephaly is accompanied by tall stature (height ≥ +2SD above the mean), and in individual 3-I, microcephaly is accompanied by short stature (height £ -2SD below the mean; Table 1 ). Three individuals (3-I, 3-III, and 6) were born small for gestational age, suggesting a potential effect on prenatal growth; however, two of these were siblings from the same consanguineous family, and we cannot rule out other genetic causes, maternal factors, exposures, or poor prenatal care without additional information. The other individual born small for gestational age (individual 6) continued to exhibit poor weight gain but developed borderline macrocephaly by 18 months of age ( Table 1) . Distinctive craniofacial features common to these patients include tall and/or broad forehead (6/11) and long face (5/11; Table 1 ). Less commonly noted were brachycephaly (4/11), short nose and long philtrum particularly in younger individuals (4/11), hypotonic facies with open mouth appearance (4/11), protruding ears (4/11), and highly arched palate (3/11; Table 1 ). A few had feeding difficulties (3/11), and eye findings including nystagmus (2/11; Table 1 ).
Five cases in three distinct families had bi-allelic variants, consistent with autosomal recessive inheritance (Table 1; Figure 1 ). Two of these individuals were compound heterozygotes, whereas the other three were siblings from a consanguineous family homozygous for the same variant (Table 1; Figure 1 ) 22 . In all three of the autosomal recessive families, at least one parent appeared mildly affected. Both parents of individual 2 had mild learning difficulties requiring individualized educational plans (IEPs) in school; in addition, the father had attention deficit hyperactivity disorder (ADHD), and the mother had a history of seizures requiring medication in childhood. The mother of individuals 3-I, 3-II, and 3-III has severe anxiety, problems with short-term memory, and borderline psychosis, whereas the parental phenotypes in family 1 appear milder with the father and unaffected sister having specific and similar mild childhood learning disabilities, and the mother having occasional depression, significant anxiety, and possible ADHD, the latter two also confirmed in her affected daughter. All parents were able to live independently and/or hold jobs.
In terms of specific variants, all five autosomal recessive cases from three distinct lineages ( Figure 1; Table 1 ) harbor either rare or novel missense changes at conserved residues within or adjacent to the catalytic domain of TET3 (Figure 2A-B) , which consists of a dioxygenase domain separated by a spacer and a cystine-rich domain (Figure 2A) (Figure 2A) .
We mapped these potential variants in TET3 to the well-conserved TET2 catalytic domain crystal structure, and all but one (p.Arg752Cys) could be visualized ( Figure 2C ). Val1089Met and Phe1072Thr are in close proximity to residue Asn1387 of TET2, which forms a hydrogen bond with the cytosine base of 5hmC to stabilize binding. Ala1076 is found adjacent to Thr1393 of TET2 which participates in hydrogen bonding with the N4 exocyclic amino group of cytosine 26 .
In addition, we identified six individuals in five families with rare mono-allelic variants in TET3 suggestive of autosomal dominant inheritance (Table 1; Figure 1 ). One was inherited, and the rest occurred de novo. In family 7, a similarly affected father and son both harbor the same frameshift variant c.4977_4983del (p.His1660ProfsTer52) in the catalytic domain (Figure 2A) , consistent with autosomal dominant inheritance. Individual 5 has a de novo nonsense variant c.5083C>T (p.Gln1695Ter) also located within the dioxygenase domain, and both this and the inherited variant occur in the last exon (Figure 2A) . Individual 8 has a de novo frameshift variant c.1215delA (p.Trp406GlyfsX135) upstream of the catalytic domain (Figure 2A) , and individuals 4 and 6 harbor de novo missense variants, namely c.2552C>T (p.Thr851Met) and c.5030C>T (p.Pro1677Leu), with the former located in the cystine-rich domain and the latter within the dioxygenase domain (Figure 2A) . Notably, in both autosomal recessive and autosomal dominant cases, all missense variants (except for p.Arg752Cys) are located within the catalytic domain (Figure 2A) , and moreover, all occurred at residues highly conserved across species with many of the variants occurring at positions also conserved among human and sometimes mouse TET enzymes ( Figure 2B) .
In the first step of DNA demethylation, 5mC is converted to 5hmC by TET enzymes 8 . To analyze the effect of individual patient variants on TET3 catalytic activity, we measured 5hmC production using a cell culture system whereby recessively inherited TET3 variants (Arg752Cys, Phe1072Thr, Ala1076Thr, Val1089Met, and Val908Leu) were overexpressed in HEK 293 cells and total 5hmC levels were measured with a dot blot assay ( Figure 3A) . We compared the activity of TET3 variants to that of a known catalytically inactive mutant (Dcat; p.H1077Y/D1079A) and to full length wild-type TET3 (Figure 3B-D) . All patient variants tested demonstrated a defect in converting 5mC to 5hmC, except for Arg752Cys (Figure 3 B,D) , which is outside the catalytic domain and not conserved among TET enzymes (Figure 2A-B) . The observed defects were consistent across biological replicates, despite fluctuations in the levels of TET3 variant expression ( Figure S1 ). For quantification, the 5hmC levels from cells expressing TET3 mutants were normalized to those measured in cells transfected with the wildtype TET3 construct to obtain a relative 5hmC signal ( Figure 3D ). These results showing decreased cellular levels of 5hmC suggest that the vast majority of the missense variants identified in affected individuals have hypomorphic function. The observation that patients with nonsense and frameshift variants have phenotypes similar to patients with hypomorphic missense variants further supports the hypothesis that decreased TET3 catalytic activity leads to disease.
Discussion
TET3, like most genes encoding components of the epigenetic machinery, is highly dosagesensitive in both model organisms and humans 1; 17; 21 . TET3 has a pLI score of 1 (observed/expected=0.02), suggesting near complete intolerance to loss of function variation 21 .
Based on this high pLI score and its high degree of coexpression across diverse tissues, TET3 was recently predicted bioinformatically to be a candidate epigenetic machinery disease gene 27 .
Consistent with dosage sensitivity, most Mendelian disorders of the epigenetic machinery are autosomal dominant due to haploinsufficiency. In line with these observations, we identified patients with mono-allelic missense or loss of function (nonsense and frameshift) variants in TET3. However, we also report individuals with overlapping phenotypes that carry bi-allelic hypomorphic missense variants, each with mildly decreased catalytic activity according to our overexpression assay. We expect that in both cases -mono-allelic loss of function mutations and bi-allelic hypomorphic mutations -there is a similar reduction in total enzymatic activity causing a conserved disease mechanism across inheritance types. Notably, nonsense and frameshift variants were only identified in the heterozygous state, suggesting that some residual TET3 activity is required for viability. Conversely, perhaps a certain threshold of TET3 activity exists, below which developmental phenotypes result regardless of whether reduced TET3 activity is caused by missense or loss of function heterozygous alleles or biallelic hypomorphic alleles.
Within our cohort we identified patients with autosomal recessive inheritance with mildly affected carrier parents, which is consistent with a causal relationship between perturbations of TET3 activity and disease manifestations and suggests an inverse correlation between residual TET3 activity and phenotypic severity. Similar examples of complex inheritance involving both mono-allelic and bi-allelic variants in another component of the epigenetic machinery, KDM5B, have been reported recently 28; 29 . An alternative hypothesis for differential modes of inheritance other than absolute activity levels could be that mono-allelic mutations have activating or dominant negative effects while bi-allelic mutations lead to loss of function; other examples of this exist in human disease 30; 31 . We cannot rule this out here because the nonsense and frameshift variants identified in families 5 and 7, respectively, are located in the last exon and may escape non-sense mediated decay, raising the possibility of a dominant negative mutation mechanism and warranting further mechanistic studies to better correlate genotype and phenotype.
Along these lines, despite the evidence for multiple modes of inheritance, we cannot discount the possibility that individuals with de novo variants have additional non-coding sequence variants in trans, given that exome sequencing, not genome sequencing, was performed. Similarly, we have not ruled out epigenetic alterations in trans, such as DNA methylation. In addition, individuals can have additional variants that contribute to their phenotype as is the case for individual 8, with a paternally inherited 16p11.2 duplication and individual 2 with a maternally-inherited 16q22.1q22.2 duplication. Further studies, including genome sequencing and methylation analysis, could shed light on the molecular mechanisms involved. However, family 7 with two sequential affected generations supports autosomal dominant inheritance, particularly when considered along with the four de novo cases. Together, our observations strongly support two distinct modes of inheritance for TET3 deficiency syndrome.
Another explanation for the observed monoallelic and biallelic cases is sex-specific differences. Notably, all probands with mono-allelic variants are male whereas all but one of the individuals with bi-allelic variants are female. While it remains true that most (if not all) of the carrier mothers appear to have mild manifestations, these were not sufficient to bring them to medical attention. It therefore remains possible that males are more susceptible to TET3 deficiency and only require a single monoallelic variant to express the full phenotype whereas females require biallelic variants. Certainly, these sex-specific findings may be due to chance given the small total number of individuals; therefore, identification of additional affected individuals and further investigation into the mechanisms associated with specific mutations is required to fully delineate the mode of pathogenesis. 
Methods

Human subjects
Written informed consent was obtained from all individuals or family member legal representatives prior to exome sequencing. Individual 1 was counseled regarding the possible outcomes of exome sequencing and signed a consent form for research-based exome sequencing through the Baylor-Hopkins Center for Mendelian Genomics, which was approved by the Johns Hopkins Institutional Review Board (IRB). The rest of the participants were recruited through GeneMatcher 25 .
Individuals 2 and 4 were consented for clinical exome sequencing through Greenwood Genetic
Center, and individual 8 was consented for clinical exome sequencing through GeneDx.
Individuals 5 and 6 were consented for clinical and/or research-based exome sequencing.
Individuals 3-I, 3-II, and 3-III were consented for research-based exome sequencing as described 22 , and individuals 7-I and 7-II were consented for research-based trio exome sequencing through the Deciphering Developmental Disorders (DDD) study 35 . 
Exome and Sanger sequencing
Cloning and plasmids
Full-length human TET3 coding sequence was amplified from cDNA and cloned into the pINTO-N3 plasmid backbone. The pINTO-N3 vector was based on the pINTO system 36 was then performed to detect 5hmC using a 5hmC antibody (Active Motif 39770).
Dot blot quantification and analysis
Dot blot quantification was performed using ImageJ as described in the ImageJ documentation.
Raw TIFF files were opened in ImageJ and the "Integrated Density" measurement of each dot was recorded after correcting for background. To account for potential differences in total DNA amount across samples, the 5hmC signal was divided by the Methylene Blue signal for each dot.
The normalized 5hmC signal was averaged across biological replicates and divided by the normalized 5hmC signal in the wild-type hTET3 transfection to obtain a relative 5hmC signal.
Samples in which the transfected mutant hTET3 was expressed at lower levels than the wild-type control were not further considered in the analysis. These were the only data points excluded from the final quantification.
Mutation Modeling
Mutations in TET3 were mapped onto the well-conserved TET2 catalytic domain crystal structure (PDB accession 5DEU 26 ) using UCSF Chimera 37 . 
